TABLE 1.
Description of the Population
| Cefazolin + Daptomycin (n = 94) | Cefazolin + Vancomycin (n = 92) | P | |
|---|---|---|---|
| Age | 62.60 ± 11.8 (23–92) | 63.94 ± 10.7 (35–89) | 0.4226 |
| Sex (male) | 41 (43.62%) | 40 (43.48%) | 0.9848 |
| Race/ethnicity (white) | 7 (92.55%) | 90 (97.83%) | 0.1692 |
| Comorbidities | |||
| DM | 30 (31.91%) | 23 (25.00%) | 0.2962 |
| CHF | 12 (12.77%) | 10 (10.87%) | 0.6889 |
| COPD | 27 (28.72%) | 29 (31.52%) | 0.6774 |
| CAD | 49 (52.13%) | 46 (50.00%) | 0.7716 |
| PVD | 85 (90.43%) | 80 (86.96%) | 0.4548 |
| Hyperlipedemia | 72 (76.60%) | 74 (80.43%) | 0.524 |
| Hypertension | 84 (89.36%) | 77 (83.70%) | 0.2573 |
| Current_smoker | 55 (58.51%) | 59 (64.13%) | 0.4314 |
| Past_smoker | 33 (35.11%) | 23 (25.00%) | 0.133 |
| Patients on oxygen | 3 (3.23%) | 5 (5.43%) | 0.4602 |
| Patients with open wound | 15 (16.13%) | 11 (11.96%) | 0.4142 |
| Patients with hospitalization in last 30 days | 32 (34.41%) | 32 (35.16%) | >0.999 |
| Patients with MRSA history | 8 (8.51%) | 3 (3.26%) | 0.1291 |
| Hemoglobin | 12.88 ± 1.8 (8.2–17.7) | 13.2 ± 2.0 (7.8–17.7) | 0.272 |
| White count | 8.12 ± 2.1 (3.8–14.1) | 8.68 ± 2.93 (3.7–18.5) | 0.1421 |
| Glucose in 24 h | 112.3 ± 27.21 (76–221) | 122.0 ± 51.96 (35–389) | 0.1212 |
| ICU LOS | 2.10 ± 1.5 (0–9) | 2.3 ± 2.0 (0–12) | 0.3546 |
*
Statistically significant.